CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dar Al Dawa Development & Investment PSC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dar Al Dawa Development & Investment PSC
9364, Naour
P.O Box
Phone: +962 62222200p:+962 62222200 AMMAN, 11191  Jordan Ticker: DADIDADI
Business Summary
Dar Al Dawa Development and Investment Company PSC is a Jordan-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical and consumer health products. The Company’s main activities are producing medical, chemical and pharmaceutical products, and importing pharmaceutical products. The Company operates an integrated network of 11 manufacturing facilities spread across Jordan, Middle East and North Africa region, as well as Romania. Its Pharmaceutical Development Unit focuses on the process developing of various dosage forms including tablets, capsules, liquids, dry suspensions, suppositories, creams, ointments, gels, parenterals, ophthalmic and nasal preparations. The Analytical Research unit engages in the analytical method development, validation, physiochemical characterization and stability studies.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2043 Cereal breakfast foods
2032 Canned specialties

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Abdul Rahim N.Jardaneh 6/6/2012
Vice Chairman of the Board Ousama M.Yaish
Chief Financial Officer Ziad N.Al Aqarba 5/8/2011 5/8/2011
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Al Dar Al Arabia Pharmaceutical Manufacturing Company
Al Dar Jordan Investment
DADI
5 additional Business Names available in full report.

General Information
Number of Employees: 858 (As of 12/31/2018)
Outstanding Shares: 35,000,000 (As of 9/30/2024)
Shareholders: 61,842
Stock Exchange: AFM
Fax Number: +962 65533199


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024